Look at it this way. Sucampo has a $225 million market cap, books 18% in US, and 40% in Japan. IRWD has a $2 Billion market cap, books 40%
in US. Plus, Sucampo will book 100% in the UK and Switzerland starting this year. All these locations for Sucampo are only for the CIC and IC indication. Plus, April 26 is the PUDUFA date for the OIC indication, which will be huge as 40% of patients have constipation while on opioid drugs. I give ( and so does the Street) a 76%-80% chance of approval for the OIC indication, simply because there have been so far, 7 million scrips written for Amitiza. I'll cover Rescula latter, but it is also approved by the fda, and will be a huge value driver for Scumpo..